Roche Withdraws Tecentriq’s Frontline Bladder Cancer Indication, Ceding Market To Keytruda

 
• By Alaric DeArment
  
Roche withdrew the first-line metastatic urothelial carcinoma indication for Tecentriq • Source: Shutterstock

More from Anticancer

More from Therapy Areas